The in-vivo assessment of cerebral amyloid load is taking a leading role in the early differential diagnosis of neurodegenerative diseases. With the hopefully near introduction of disease-modifying drugs, we expect a paradigm shift in the current diagnostic pathway with an unprecedented surge in the request of exams and detailed analysis.
-
May 22, 2018 (v1)PublicationUploaded on: April 14, 2023
-
2018 (v1)Publication
Background: We explored the presence of both reserve and resilience in late-converter mild cognitive impairment due to Alzheimer's disease (MCI-AD) and in patients with slowly progressing amyloid-positive MCI by assessing the topography and extent of neurodegeneration with respect to both "aggressive" and typically progressing phenotypes and in...
Uploaded on: April 14, 2023